Full metadata record
DC FieldValueLanguage
dc.creatorMuñiz-Sáenz-Diez, J. (Javier)-
dc.creatorEzponda, A. (Ana)-
dc.creatorCaballeros, M. (Meylin)-
dc.creatorFuente, A. (Ana) de la-
dc.creatorGavira, J.J. (Juan José)-
dc.creatorBastarrika, G. (Gorka)-
dc.date.accessioned2023-11-21T11:33:26Z-
dc.date.available2023-11-21T11:33:26Z-
dc.date.issued2023-
dc.identifier.citationMuñiz-Sáenz-Diez, J. (Javier); Ezponda, A. (Ana); Caballeros, M. (Meylin); et al. "Safety, feasibility, and hemodynamic response of regadenoson for stress perfusion CMR". The International Journal of Cardiovascular Imaging. 39 (9), 2023, 1765 - 1774es_ES
dc.identifier.issn1875-8312-
dc.identifier.urihttps://hdl.handle.net/10171/67912-
dc.description.abstractOwing to its pharmacodynamics and posology, the use of regadenoson for stress cardiac magnetic resonance (CMR) has potential advantages over other vasodilators. We sought to evaluate the safety, hemodynamic response and diagnostic performance of regadenoson stress-CMR in routine clinical practice. All regadenoson stress-CMR examinations performed between May 2017 and July 2020 at our institution were retrospectively reviewed. A total of 698 studies were included for the final analysis. A conventional stress/rest protocol was performed using a 1.5T MRI scanner (Magnetom Aera, Siemens Healthineers, Erlangen, Germany). Adverse events, clinical symptoms, and hemodynamic response were assessed. Diagnostic accuracy of the test was evaluated in patients who underwent invasive coronary angiography. Nearly half of patients (48.5%) remained asymptomatic. Most common clinical symptoms included dyspnea (137, 19.6%), chest pain (116, 16.6%) and flushing (44, 6.3%). Two patients (0.28%) could not complete the examination due to severe hypotension or unbearable chest pain. Overall, an increase in heart rate (HR) response (36.2% [IQR: 22.5–50.9]) and a decrease in systolic and diastolic blood pressure (BP) (median systolic BP response of -5% [IQR: -11.5-0.6]; median diastolic BP response of -6.3 mmHg [IQR: -13.4-0]) was observed. Patients with symptoms induced by regadenoson showed higher HR response (40.3%, IQR: 26.4–56.1 vs. 32.4%, IQR: 19-45.6, p<0.001), whereas a blunted HR response was observed in diabetic (29.6%, IQR: 18.4–42 p<0.001), obese (31.7%, IQR: 20.7–46.2 p=0.005) and patients aged 70 years or older (32.9%, IQR: 22.6–43.1 p<0.001). Overall, regadenoson stress-CMR showed 95.65% (IQ 91.49–99.81) sensitivity, 54.84% (IQ 35.71–73.97) specificity, 86.99% (IQ 82.74–94.68) positive predictive value, and 77.27% (IQ 57.49–97.06) negative predictive value for detecting significant coronary stenosis as compared with invasive coronary angiography. Regadenoson is a well-tolerated vasodilator that can be safely employed for stress perfusion CMR, with high diagnostic performancees_ES
dc.description.sponsorshipOpen Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature.es_ES
dc.language.isoenges_ES
dc.publisherSpringeres_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.subjectCoronary artery diseasees_ES
dc.subjectMyocardial perfusiones_ES
dc.subjectRegadenosones_ES
dc.subjectPerfusion cardiac magnetic resonancees_ES
dc.subjectDrug safetyes_ES
dc.titleSafety, feasibility, and hemodynamic response of regadenoson for stress perfusion CMRes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.description.noteThis article is licensed under a Creative Commons Attribution 4.0 International Licensees_ES
dc.identifier.doi10.1007/s10554-023-02877-z-
dadun.citation.endingPage1774es_ES
dadun.citation.number9es_ES
dadun.citation.publicationNameThe International Journal of Cardiovascular Imaginges_ES
dadun.citation.startingPage1765es_ES
dadun.citation.volume39es_ES
dc.identifier.pmid37354385-

Files in This Item:
Thumbnail
File
s10554-023-02877-z.pdf
Description
Size
1.76 MB
Format
Adobe PDF


Statistics and impact
0 citas en
0 citas en

Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.